patent on semaglutide Brazilian federal court denies extension Off-patent semaglutide in 2026: the

By engaging GIP, GLP-1, and GCG receptors, it aims to suppress appetite, enhance glycemic control, and promote energy expenditure

Semaglutide is the active ingredient in injectable glucagon-like peptide-1 (GLP-1) agonist that is administered once weekly to aid in weight loss

If you are having surgery or deep sedation, tell your surgeon, anaesthetist and prescribing doctor that you use a GLP-1 or dual GIP/GLP-1 medicine, as Australian guidance has highlighted risks related to delayed gastric emptying and aspiration during anaesthesia or deep sedation

[ COMFORTABLE USE VEGETABLE CAPSULES ] Presentation in easy-to-take vegetable capsules, designed to integrate seamlessly into your daily routine, whether in the morning, before the study or during days with high mental demand